Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 6/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29268998 | 1.00 | HDAC1 (0.42) | HDAC1HDAC6USP30MEN1KMT2A | |
| SCHEMBL30474006 | 1.00 | HDAC1 (0.42) | HDAC1HDAC6USP30MEN1KMT2A | |
| SCHEMBL29268997 | 1.00 | HDAC1 (0.42) | HDAC1HDAC6USP30MEN1KMT2A | |
| SCHEMBL29268985 | 0.92 | HDAC1 (0.42) | HDAC1HDAC6USP30RORCGABRA5 | |
| SCHEMBL30474034 | 0.92 | HDAC1 (0.42) | HDAC1HDAC6USP30RORCGABRA5 | |
| SCHEMBL29268982 | 0.92 | HDAC1 (0.42) | HDAC1HDAC6USP30RORCGABRA5 | |
| SCHEMBL25675712 | 0.91 | FAAH (0.34) | HDAC1HDAC6USP30RORC | |
| SCHEMBL30474019 | 0.91 | FAAH (0.34) | HDAC1HDAC6USP30RORC | |
| SCHEMBL24073258 | 0.90 | HDAC1 (0.44) | HDAC1HDAC6USP30RORC | |
| SCHEMBL30473982 | 0.90 | PIK3CD (0.36) | HDAC1HDAC6USP30RORCGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023099561-A1 | SUBSTITUTED N-CYANOPYRROLIDINES WITH ACTIVITY AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2023-06-08 | — | — | WO | disclosed |